Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health's SEC filings reveal how a dual-segment animal health company allocates resources between pet care products and farm animal solutions. The 10-K annual reports break down revenue by companion animal and farm animal segments, showing which product categories and geographic regions drive growth. Our AI summaries highlight these segment breakdowns so you can quickly assess performance without navigating hundreds of pages of regulatory text.
The company's 10-Q quarterly filings provide interim updates on segment performance, inventory levels, and research spending. For an animal health company with diverse product lines across parasiticides, dermatology, and nutritional health, these quarterly disclosures track how individual therapeutic categories perform through seasonal cycles and competitive pressures. AI-powered analysis identifies the key metrics and management commentary that matter most.
Form 4 insider transactions document when Elanco executives and directors buy or sell company shares. Monitoring these filings helps investors understand how leadership views the stock's value relative to their compensation and investment decisions. Our platform tracks these transactions in real-time as they post to EDGAR, eliminating the need to manually search SEC databases.
8-K filings capture material events including strategic acquisitions, licensing agreements, and leadership changes. For a company that grows through both internal R&D and external partnerships, these filings provide timely notice of transactions that affect competitive positioning. The DEF 14A proxy statement details executive compensation structures, board composition, and shareholder voting matters relevant to corporate governance assessment.
Access Elanco's complete SEC filing history with AI explanations that translate regulatory language into clear insights about business performance, financial health, and corporate strategy.
Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Elanco Animal Health director reports equity grant
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a reported price of $0, reflecting that this was an equity grant rather than an open‑market purchase. Following this transaction, the director beneficially owned 91,278 shares of Elanco common stock in direct ownership. The award is described as part of the regular annual equity compensation for non‑employee members of the company’s Board of Directors.
Elanco Animal Health Inc. (ELAN) reported an insider equity award for a member of its Board of Directors. On 11/28/2025, director Michael J. Harrington received 10,314 shares of common stock, recorded at a price of $0 per share, reflecting a grant rather than a market purchase. Following this transaction, he beneficially owned 109,577 shares of Elanco common stock in direct ownership. The company explains that this grant represents deferred stock units issued as an annual equity award to each non-employee member of the Board of Directors, aligning director compensation with shareholder interests through stock-based incentives.
Elanco Animal Health Inc. (ELAN)67.0754 deferred stock units at a price of $21.09 per unit. Following this transaction, he beneficially owns 7,230.2452 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these deferred stock units will settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health Inc. executive Jeffrey N. Simmons, the company’s President, CEO and Director, reported a new equity-related award. On 11/14/2025, he acquired 131.3058 deferred stock units at a reference price of $21.09 per unit. After this transaction, he beneficially owned 18,355.9214 derivative securities, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units are designed to settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 31,547,970 shares (6.4%) of Elanco Animal Health common stock as of 09/30/2025.
The filer reports sole voting power over 31,482,581 shares and sole dispositive power over 31,547,970 shares, with no shared voting or dispositive power. It certifies the holdings were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
Elanco Animal Health (ELAN) filed its Q3 2025 10‑Q, reporting revenue of $1,137 million, up from $1,030 million a year ago. Gross profit was $607 million. The quarter showed a net loss of $34 million (basic and diluted EPS of $(0.07)), compared to a prior-year period boosted by a $640 million gain on an asset sale. Year-to-date net income was $44 million.
Pet Health revenue was $533 million and Farm Animal totaled $593 million. Operating cash flow for the first nine months reached $452 million. Cash was $505 million, and long‑term debt (excluding finance lease) was $3,769 million, down from $4,321 million at year‑end. In May, Elanco monetized certain future XDEMVY royalties for $295 million, recorded as a $300 million liability with a 16.2% effective interest rate. Subsequent to quarter‑end, the company refinanced debt with new facilities and fully repaid its prior Term Loan B; the weighted‑average effective interest rate decreased to 5.77% as of October 31, 2025. Shares outstanding were 496,863,473 as of October 31, 2025.
Elanco Animal Health (ELAN) furnished a Current Report announcing results for the fiscal quarter ended September 30, 2025, along with guidance for the full year and fourth quarter of 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025.
The Item 2.02 information, including Exhibit 99.1, was furnished and is not deemed filed under the Exchange Act.
Elanco Animal Health (ELAN) reported that President, CEO and Director Jeffrey N. Simmons acquired 125.0221 deferred stock units on 10/31/2025 at $22.15 per unit. Following this transaction, he beneficially owns 18,224.6156 derivative securities, held as direct ownership.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
